Molecular imaging of HER2-positive breast cancer: A step toward an individualized 'image and treat' strategy

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 559-566

  Capala, Jacek ^a   Bouchelouche, Kirsten ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

breast cancer; HER2; magnetic resonance imaging; molecular imaging; optical imaging; positron emission tomography; single photon emission tomography

Indexed keywords

(4 FLUOROBENZAMIDO)ETHYL MALEIMIDE ZHER2:342 F 18; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID C 64; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID MUT DS GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID ZHER2:477 CU 64; ABY 002 GA 68; ABY 002 IN 111; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; INDOCYANINE GREEN; PENTETATE PERTUZUMAB IN 111; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE; TRASTUZUMAB I 124; TRASTUZUMAB IN 111; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG; ZHER2:2395 CYS TC 99M; ZHER2:342 I 124;

BIOLUMINESCENCE; BREAST BIOPSY; BREAST CANCER; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG UPTAKE; FLUORESCENCE IN SITU HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MOLECULAR IMAGING; RECEPTOR, ERBB-2;

EID: 77958484636     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833f8c3a     Document Type: Review

References (47)

1. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505-516.
2. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006; 12:6326-6330.
3. Chevallier P, Robillard N, Wuilleme-Toumi S, et al. Overexpression of Her2/ neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. Haematologica 2004; 89:1399-1401.
4. Serrano-Olvera A, Duenas-Gonzalez A, Gallardo-Rincon D, et al. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 2006; 32:180-190.
5. Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol 2001; 12 (Suppl 1):S81-S87.
6. Ignatiadis M, DesmedtC, Sotiriou C, et al. HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009; 15:1848-1852.
7. Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008; 8:38-49.
8. Sanchez-Munoz A, Perez-Ruiz E, Jimenez B, et al. Targeted therapy of metastatic breast cancer. Clin Transl Oncol 2009; 11:643-650.
9. Brufsky A. Trastuzumab-based therapy for patients with HER2-positive breast cancer: from early scientific development to foundation of care. Am J Clin Oncol 2010; 33:186-195.
10. Desmedt C, Sperinde J, Piette F, et al. Quantitation of HER2 expression or HER2 : HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. Diagn Mol Pathol 2009; 18:22-29.
11. Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol 2003; 119:381-387.
12. Allison M. The HER2 testing conundrum. Nat Biotechnol 2010; 28:117-119.
13. Allred DC. Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol 2010; 23 (Suppl 2): S52-S59.
14. Phillips KA, Marshall DA, Haas JS, et al. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 2009; 115:5166-5174.
15. Benson JR, Jatoi I, Keisch M, et al. Early breast cancer. Lancet 2009; 373:1463-1479.
16. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009; 10:1179-1187.
17. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122:999-1004.
18. Krawczyk N, Banys M, Neubauer H, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 2009; 29:4019-4024.
19. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 2007; 19:552-557.
20. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14:2999-3019.
21. 89Zr-trastuzumabfor HER2/neu immunoPET imaging. J Nucl Med 2009; 50:974-981.
22. Oude Munnink TH, Korte MA, Nagengast WB, et al. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur J Cancer 2010; 46:678-684.
23. 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010; 87:586-592.
24. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol 2010; 398:232-247.
25. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010; 584:2670-2680.
26. 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med 2009; 50:417-425.
27. Tolmachev V, Velikyan I, Sandstrom M, Orlova A. A HER2-binding affibody molecule labelled with (68)Ga for PET imaging: direct in vivo comparison withthe (111)In-labelled analogue. Eur J Nucl Med Mol Imaging 2010; 37:1356-1367.
28. 68Ga-labeled affibody molecules. J Nucl Med 2010; 51:892-897.
29. 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2010; 12:316-324.
30. Kiesewetter DO, Kramer-Marek G, Ma Y, Capala J. Radiolabelling of Her2 specific affibody molecule with F-18. J Fluorine Chem 2008; 129:799-805.
31. Kramer-Marek G, Kiesewetter DO, Martiniova L, et al. [18F]FBEM-Z(HER2: 342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008; 35:1008-1018.
32. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med 2009; 50:1131-1139.
33. 68Gafor PET imaging of HER2 expression. J Nucl Med 2009; 50:1492-1499.
34. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumourxenografts. Eur J Nucl Med Mol Imaging 2009; 36:81-93.
35. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009; 50:1340-1348.
36. 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 2009; 50:781-789.
37. Chen TJ, Cheng TH, Chen CY, et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009; 14:253-260.
38. Kinoshita M, Yoshioka Y, Okita Y, et al. MR molecular imaging of HER-2 in a murine tumor xenograft by SPIO labeling of anti-HER-2 affibody. ContrastMedia Mol Imaging 2010; 5:18-22.
39. Urano Y, Asanuma D, Hama Y, et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009;15:104-109.
40. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging oftumors with near-infrared fluorescent ligands. Nat Biotechnol 2001; 19:327-331.
41. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt 2001; 6:122-133.
42. Engelbrecht CJ, Johnston RS, Seibel EJ, Helmchen F. Ultra-compact fiber-optic two-photon microscope for functional fluorescence imaging in vivo. Opt Express 2008; 16:5556-5564.
43. Masotti A, Vicennati P, Boschi F, et al. A novel near-infrared indocyanine dye-polyethylenimine conjugate allows DNA delivery imaging in vivo. Bioconjug Chem 2008; 19:983-987.
44. Mitra S, Foster TH. In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. Neoplasia 2008; 10:429-438.
45. Ogawa M, Regino CA, Seidel J, et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide forspecific and quantitative targeted cancer detection. Bioconjug Chem 2009;20:2177-2184.
46. Chernomordik V, Hassan M, Lee SB, et al. Quantitative analysis of HER2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging2010; 9:192-200.
47. Lee SB, Hassan M, Fisher R, et al. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res2008; 14:3840-3849.